Calcium D-Glucarate
SupplementThe substantial divergence arises from the fact that medical evidence is based exclusively on animal and in vitro data as well as preliminary human observations [s4, s9], while the community rates it considerably more positively based on subjective experiences and plausibility arguments [c1, c2]. A classic case of mechanism-of-action enthusiasm without RCT confirmation.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Calcium-D-glucarate inhibits beta-glucuronidase and is theorized to improve excretion of estrogens and other glucuronidated compounds — the mechanism is plausible, but robust human RCTs are entirely absent. The community uses it primarily for estrogen dominance and in TRT contexts, often stacked with DIM, with mostly positive but far from unanimous feedback. Initial headaches and brain fog in the first weeks of use are commonly reported. Anyone taking glucuronidated drugs like ibuprofen, lorazepam, or morphine alongside it should proceed with caution.
Description
Calcium salt of D-glucaric acid; inhibits beta-glucuronidase and is purported to support glucuronidation. Evidence from animal and in vitro studies; robust human RCTs are lacking. [s1, s2]
Calcium-D-glucarate is the calcium salt of D-glucaric acid, a compound that occurs naturally in small amounts in foods such as oranges, grapefruit, apples, and broccoli, and is also produced in the human body [s2, s5]. It is available as a dietary supplement in concentrated form. In the body, calcium-D-glucarate is hydrolyzed to release D-glucaric acid, which is further metabolized to D-glucaro-1,4-lactone (1,4-GL) [s1, s2]. This metabolite is considered the pharmacologically active compound, acting as an inhibitor of the enzyme beta-glucuronidase [s1, s3, s4]. Beta-glucuronidase cleaves glucuronidated compounds, which can lead to reabsorption of already-conjugated substances (e.g., estrogens, carcinogens, bile acids) from the intestine [s3, s4, s5]. By inhibiting this enzyme, calcium-D-glucarate is proposed to promote excretion of these compounds and support phase II liver function (glucuronidation) [s3, s5, s6]. Animal studies show positive effects on tumor development, estrogen metabolism, and lipid levels [s6, s7, s8]. Clinical evidence in humans is, however, very limited: no completed, published RCTs exist that clearly demonstrate efficacy for breast, prostate, or colorectal cancer prevention, estrogen regulation, or liver function in humans [s4, s5, s9]. A 2002 monograph review (Alternative Medicine Review) cites preliminary human findings on cholesterol reduction, but these have not been confirmed in peer-reviewed RCTs [s9]. Calcium-D-glucarate is frequently marketed in the context of estrogen dominance, hormonal balance, and liver metabolism. These indications are mechanistically plausible but clinically insufficiently substantiated [s4, s5, s9].
Legal Status (DE)
{'novel_food_note': 'NOTE (Gap 8+9): The EU novel food status of calcium-D-glucarate / D-glucaric acid could not be directly verified in the EU Novel Food Catalogue (ec.europa.eu), as no corresponding search results were obtained on the official EU website. BfR opinions on glucaric acid / calcium-D-glucarate as a dietary supplement were also not found. The previous text ("no specific EFSA or BfR authorization as a novel food") remains unchanged, as neither a listing nor an official rejection could be primarily substantiated. Recommendation: manual verification required at https://ec.europa.eu/food/novel-food/catalogue/. '}
Mechanism of Action
Following oral ingestion, calcium-D-glucarate is hydrolyzed to release D-glucaric acid, which is metabolized in the body to D-glucaro-1,4-lactone (1,4-GL) [s1, s2]. 1,4-GL is a competitive inhibitor of beta-glucuronidase — an enzyme found in the intestine, liver, and other tissues that cleaves glucuronidated conjugates [s1, s3]. Glucuronidation is a central phase II biotransformation reaction in the liver: toxins, steroid hormones (particularly estrogens), drug metabolites, and carcinogens are conjugated to glucuronic acid, rendered more water-soluble, and excreted via bile or urine [s3, s5, s6]. However, intestinal beta-glucuronidase can cleave these conjugates and lead to reabsorption [s3, s4]. By inhibiting beta-glucuronidase with 1,4-GL, this enterohepatic circulation is proposed to be reduced, allowing more conjugated estrogen and other metabolites to be definitively excreted [s3, s4, s5]. Calcium-D-glucarate is suggested to exert a longer inhibitory effect on beta-glucuronidase than D-glucaro-1,4-lactone itself, as it acts as a sustained-release form [s3]. Animal studies have also observed cholesterol-lowering effects, possibly mediated through increased bile acid excretion [s7, s8]. Whether these mechanisms are clinically relevant in humans has not been sufficiently established [s4, s5, s9].
Dosing
Allgemeine Leberunterstützung / Östrogenmetabolismus
- Dose
- 500–1500 mg
- Frequency
- 1–3× täglich
- Route
- oral
- Duration
- mindestens 6–12 Wochen
- Timing
- Take with a meal
- With food
- empfohlen
Chemopräventive Dosierung (Tierversuch-Extrapolation)
- Dose
- 1500–3000 mg
- Frequency
- aufgeteilt auf 3 Dosen
- Route
- oral
- Duration
- nicht definiert (keine Humandaten)
- Timing
- With meals
- With food
- empfohlen
No official BfR- or EFSA-established upper limit exists for calcium-D-glucarate. High doses were tolerated without toxic effects in animal studies [s10]. Human safety upper limit not defined [s9].
Dosing information is based on manufacturer recommendations and a monograph review [s9]; no basis in human RCTs. Intake with a meal is recommended [s10].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, weicher Stuhl, Bauchkrämpfe) Generally considered well tolerated; gastrointestinal symptoms are occasionally reported at higher doses [s9, s10]. | gelegentlich | leicht |
| Kopfschmerzen und Brain Fog in den ersten Einnahmewochen User reports in Reddit forums describe possible 'detox reactions' at the start of supplementation; mechanistic basis unclear [c1]. | selten | leicht |
| Potenzielle Beeinflussung des Östrogenspiegels Inhibition of beta-glucuronidase may increase estrogen excretion, which can be undesirable in individuals with low estrogen levels [s4, s5]. | theoretisch | moderat |
Contraindications
No safety data available for pregnant or breastfeeding women; potential interference with hormonal balance. Use not recommended [s9, s10].
Calcium-D-glucarate may affect estrogen levels. Medical consultation is mandatory when undergoing hormone therapy or anti-estrogen treatment [s4, s5].
Calcium-D-glucarate is metabolized hepatically. In severely impaired hepatic function, the metabolic status is unclear [s9].
Interactions
Synergistic
DIM promotes the 2-hydroxylation pathway of estrogen metabolism in the liver, while calcium D-glucarate ensures excretion of these metabolites by inhibiting beta-glucuronidase. The combination is considered synergistic for a balanced estrogen profile.
Caution
Calcium-D-glucarate inhibits β-glucuronidase and can thereby influence hepatic glucuronidation and the detoxification of alcohol metabolites, potentially altering the elimination of ethanol-induced toxic intermediates.
Calcium-D-glucarate inhibits intestinal β-glucuronidase and may thereby reduce the enterohepatic recirculation of enclomiphene, potentially leading to altered plasma levels and reduced efficacy of the drug.
Calcium-D-glucarate accelerates the glucuronidation of steroid hormones including DHEA and its metabolites. This may reduce the duration of action and plasma levels of exogenously administered DHEA.
Studies
Tier A — High Evidence
Community Evidence
Top reported benefits
- Perceived improvement of estrogen-related symptoms (e.g., water retention, PMS)
- Subjective sense of improved detoxification and liver support
- Combination with DIM perceived as beneficial
- Positive effect on hormonal balance in men (estrogen reduction during TRT)
Top reported issues
- Headaches and brain fog during the first weeks of use ('detox reaction')
- No noticeable effects in a subset of users
- Uncertainty about optimal dosing
Some users report pronounced initial complaints (headaches, fatigue) and inquire about their cause [c1]. Community evidence is overall thin; the total number of analyzed posts is below 30, as CDG is a niche product in the DACH region and internationally. Users frequently conflate mechanistic plausibility with clinical efficacy.
Scientific Sources
- Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits
Walaszek Z, Hanausek-Walaszek M, Minton JP, et al. (1990). Cancer LettersCPMID:2346674 - Calcium D-Glucarate – Uses, Side Effects, Precautions, Interactions, Dosing
WebMD / RxList Editorial Staff (2023). WebMD Vitamins & Supplements DatabaseCLink - Calcium D-glucarate – Drug interactions (Alcohol, glucuronidated drugs)
RxList Editorial Staff (2023). RxList Supplements DatabaseCLink - Neuartige Lebensmittel (Novel Food) – BVL Informationsseite
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2023). BVL DeutschlandALink - Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis
Abou-Issa H, Moeschberger M, el-Masry W, Tejwani S, Curley RW Jr, Webb TE (1995). Anticancer ResCPMID:7645962 - Calcium-D-glucarate (Monograph entry)
PubMed abstract entry (2002). Alternative Medicine ReviewBPMID:12197785 - Calcium D-Glucarate Naturally Enhancing Glucuronidation
Douglas Laboratories (2010). Douglas Laboratories Technical ReportCLink - Calcium Glucarate – Integrative Medicine Overview
Memorial Sloan Kettering Cancer Center (2023). MSKCC Integrative Medicine DatabaseBLink - Calcium D-Glucarate – Wikipedia Overview with cited references
Wikipedia contributors (2024). WikipediaCLink - Calcium glucarate as a chemopreventive agent in breast cancer
Abou-Issa H, Moeschberger M, el-Masry W, et al. (1995). Anticancer ResearchCPMID:7744577 - Animal studies on cholesterol-lowering effects of calcium D-glucarate (referenced in review)
Referenced via SelfDecode Supplements review (2022). SelfDecode Review SummaryCLink - Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention
Walaszek Z, Szemraj J, Narog M, et al. (1997). Nutrition and CancerCPMID:9101079 - Calcium-D-glucarate (Full Monograph)
Calcium-D-Glucarate monograph authors (2002). Alternative Medicine ReviewBPMID:12197785
Community Sources
Storage
Unopened
Store in a dry place at room temperature, protected from light and moisture.
Opened
Keep container tightly closed; avoid moisture.